The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integration of clinical trial development in hematology and oncology fellowship training: Washington University School of Medicine experience.
 
Christine Auberle
Stock and Other Ownership Interests - Amgen (I); Bristol-Myers Squibb (I); G1 Therapeutics (I); Merck (I); UnitedHealthcare (I)
 
Feng Gao
No Relationships to Disclose
 
Ningying Wu
No Relationships to Disclose
 
Stuart Kornfeld
Employment - M6P Therapeutics
Leadership - Amicus Therapeutics
Consulting or Advisory Role - Amicus Therapeutics
Patents, Royalties, Other Intellectual Property - M6P Therapeutics
 
Joel Picus
Consulting or Advisory Role - Pfizer
Research Funding - BioClin Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Mirati Therapeutics (Inst); Seagen (Inst); TRACON Pharma (Inst)
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)
 
Morey Blinder
Consulting or Advisory Role - Agios
 
John Sutton Welch
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen Oncology (Inst); Notable Labs (Inst)
 
Sana Saif Ur Rehman
No Relationships to Disclose
 
Keith Stockerl-Goldstein
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Novartis; Novartis
Honoraria - GlaxoSmithKline; Janssen
Research Funding - BiolineRx; Caelum Biosciences; GlaxoSmithKline; Glycomimetics; Ionis Pharmaceuticals; Janssen; Sanofi; Takeda; Zentalis
Expert Testimony - Celgene
Other Relationship - Cellerant
 
Neha Mehta-Shah
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Genentech/Roche; Kyowa Hakko Kirin; Secura Bio
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo; Dizal Pharma (Inst); Genentech/Roche (Inst); Innate Pharma (Inst); Verastem (Inst); Yingli Pharma (Inst)
 
Elaine M. Majerus
Stock and Other Ownership Interests - Cigna/Evernorth Health; Merck; Merck; Regeneron; Viking Therapeutics
Consulting or Advisory Role - Apellis Pharmaceuticals; Biomarin; Genentech; Spark Therapeutics
 
Stephen Oh
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Cogent Biosciences; Constellation Pharmaceuticals; CTI BioPharma Corp; Geron; Incyte; Protagonist Therapeutics; Sierra Oncology
Research Funding - Actuate Therapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Pharmaessentia (Inst); Sierra Oncology (Inst); Takeda (Inst)
 
Peter Westervelt
Consulting or Advisory Role - Pfizer
 
Ramaswamy Govindan
Consulting or Advisory Role - Jacobio; Merck; Precisca
 
Daniel C Link
No Relationships to Disclose
 
John F. DiPersio
Stock and Other Ownership Interests - Magenta Therapeutics; WUGEN, Inc.
Honoraria - Incyte
Consulting or Advisory Role - Amgen; Incyte; Magenta Therapeutics; Partner Therapeutics; Rivervest
Research Funding - Amphivena Therapeutics (Inst); Bigelow Aerospace (Inst); BiolineRx (Inst); Incyte (Inst); Macrogenics (Inst); Maxcyte (Inst); NeoImmuneTech (Inst); WUGEN, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - CD7 and CD2 Knockout for CART to CD7 and CDL; Combining integrin inhibitor with chemokine binders, 016131; Dextran based molecules to detect CAR-T cells; Duvelisib for treatment of cytokine release syndrome (CRS); IFNg, upregulate MHCII for relapsed AML; JAK and calcineurin inhibition, solid organ transplant; Novel WU mobilizing compounds (Inst); NT-17 to enhance CART Survival; Selection of IMPDH Mutant Stem Cells; Targeting IFNR/CSCR3 in GvHD; Triple Combination - CXCR2, VLA-4, gro-b; VLA4, gro-b; WU/SLU compounds VLA4 and CXCR2 (Inst)
Travel, Accommodations, Expenses - Amgen; Celgene; Cerus; Incyte; Novartis; Partner Therapeutics
 
Saiama Naheed Waqar
Research Funding - Abbvie (Inst); ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cullinan Pearl (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Millennium (Inst); Newlink Genetics (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Roche (Inst); Verastem (Inst); Vertex (Inst); Xcovery (Inst)
 
Lee Ratner
No Relationships to Disclose